Economic analysis of zanubrutinib vs. acalabrutinib in B-cell malignancies
Economic analysis of zanubrutinib vs. acalabrutinib in
Relative efficacy of several treatment options in marginal zone lymphoma
Relative efficacy of several treatment options in marg
Follicular lymphoma: news on bispecific antibody treatment
Follicular lymphoma: news on bispecific antibody treat
Innovative BCL2 inhibition: indications fanning out across B-cell malignancies
Innovative BCL2 inhibition: indications fanning
BTK degraders: emerging activity in various B-cell malignancies
BTK degraders: emerging activity in various B-ce
Meeting unmet needs in mantle cell lymphoma
Meeting unmet needs in mantle cell lymphoma
Reducing risks further in chronic lymphocytic leukemia
Reducing risks further in chronic lymphocytic leukemia
Preface – EHA 2024
Preface – EHA 2024 © private – Sigrid S. Skånland,
Innovative agents in marginal zone lymphoma and other B-cell malignancies
Innovative agents in marginal zone lymphoma and
Exploring chemotherapy-free approaches in the treatment of DLBCL
Exploring chemotherapy-free approaches in the tr
